580 related articles for article (PubMed ID: 19135705)
21. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
[TBL] [Abstract][Full Text] [Related]
22. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
[TBL] [Abstract][Full Text] [Related]
23. Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.
Metzler H; Prüller F; Münch A; Primus G; Kainz J; Hödl R; Rehak P
Eur J Anaesthesiol; 2010 Feb; 27(2):138-45. PubMed ID: 19593147
[TBL] [Abstract][Full Text] [Related]
24. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
[TBL] [Abstract][Full Text] [Related]
25. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
[TBL] [Abstract][Full Text] [Related]
28. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
[TBL] [Abstract][Full Text] [Related]
29. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
[TBL] [Abstract][Full Text] [Related]
30. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
[TBL] [Abstract][Full Text] [Related]
31. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
Cotton JM; Worrall AM; Hobson AR; Smallwood A; Amoah V; Dunmore S; Nevill AM; Raghuraman RP; Vickers J; Curzen N
Cardiovasc Ther; 2010 Jun; 28(3):139-46. PubMed ID: 20406238
[TBL] [Abstract][Full Text] [Related]
32. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
[TBL] [Abstract][Full Text] [Related]
33. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Shenkman B; Matetzky S; Fefer P; Hod H; Einav Y; Lubetsky A; Varon D; Savion N
Thromb Res; 2008; 122(3):336-45. PubMed ID: 18155752
[TBL] [Abstract][Full Text] [Related]
34. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
[TBL] [Abstract][Full Text] [Related]
36. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
[TBL] [Abstract][Full Text] [Related]
37. Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting.
Weltermann A; Fritsch P; Kyrle PA; Schoenauer V; Heinze G; Wojta J; Christ G; Huber K
Thromb Res; 2003; 112(1-2):19-24. PubMed ID: 15013268
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
Thromb Res; 2009 Sep; 124(4):418-22. PubMed ID: 19250657
[TBL] [Abstract][Full Text] [Related]
40. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
